Psoriatic arthritis (PsA) is plagued by obesity, depression and increased comorbidities; now it appears that polypharmacy adds to the burden of managing PsA.
A study of 11,984 PsA patients in the German BARMER health insurance database from 2021 compared medicines and comorbidities with sex-matched and age-matched controls without inflammatory arthritis. Polypharmacy was defined as ≥5 concomitant drugs.
Dr. John Cush RheumNow
3 years 5 months ago
Open-label trial of Guselkumab (IL-23 inhib) in 20 moderate-to-severe hidradenitis suppurativa (HS) pts saw 65% with HiSCR response at wk 16. Yet phase IIB NOVA PBO-RCT showed GUS HiSCR response 45–51% (vs 39% PBO). GUS may only benefit subgroup of HS https://t.co/OxtFfyRMFk https://t.co/hnQyU0VWxg
Dr. John Cush RheumNow
3 years 5 months ago
Cost-Effective Use of Biological and Targeted Synthetic DMARDs
An international task force of experts have developed evidence-based points to consider regarding the cost-effective use of b/tsDMARDs in the treatment of inflammatory rheumatic diseases.
https://t.co/jpxQggd89T https://t.co/zjer5QTN3C
Dr. John Cush RheumNow
3 years 5 months ago
Optimal Timing of Elective Hip or Knee Arthroplasty
https://t.co/Dz7qHxS5aO https://t.co/z7Q2oReEJs
Dr. John Cush RheumNow
3 years 5 months ago
Congratulations to Dr. Georg Schett (University of Erlangen) upon receiving the 2023 Gottfried Wilhelm Leibniz Prize - highest honor from the DFG, German Research Foundation. Dr. Schett is famed for research on inflammation, autoimmunity & osteoimmunology https://t.co/Wq0EvhtvLW https://t.co/AWwCVCt4cm
A research report in JAMA Dermatology describes the use of the type 1 interferon receptor inhibitor anifrolumab in patients with chronic discoid lupus erythematosus (DLE).
Researchers have revealed the modulatory effect of the anti-inflammatory metabolite itaconate (ITA) on T helper and T regulatory cells, which may lead to new therapeutic approaches to treating some autoimmune diseases.
Dr. John Cush RheumNow
3 years 5 months ago
Lancet metanalysis shows pts infected w/ SARS-CoV2 are conferred very high degree of re-infx from pre-omicron variants, even after 40 weeks. Protection was lower for omicron BA.1 & declined over time. Protection from severe Dz was high for all variants. https://t.co/RNgYVWQfNo https://t.co/J8U37NYXPP
Dr. John Cush RheumNow
3 years 5 months ago
Carpal Tunnel - Steroid injection vs. Night Splinting
A randomized trial conducted by the UK National Health Service, studied interventions in patients with CTS and found no advantage to either CTS CSIor NS as the initial treatment of CTS.
https://t.co/05AADf55uB https://t.co/m07xxffSfv
Dr. John Cush RheumNow
3 years 5 months ago
Ccancer detection study in idiopathic inflammatory myositis: found w/in 3 yrs of onset 9/1011 (0.9%) CT chest & 12/657(1.8%) CT Dx cancer. Yield best w/ DM, TIF1γ pos. Yield very low age<40 yrs; high false(+) w/ antisynthetase synd & necrotizing myositis https://t.co/FCBwEYW1eT https://t.co/DAEj83xmam
Dr. John Cush RheumNow
3 years 5 months ago
Marathon Running Not a Risk Factor for Arthritis
Intensity of distance running had no bearing on the prevalence of hip and knee osteoarthritis among participants in recent editions of the Chicago Marathon, researchers reported here.
https://t.co/GjgyncTGa6 https://t.co/cwIADHfNdv
Dr. John Cush RheumNow
3 years 5 months ago
29 pts w/PsA Sine Psoriasis: 16F/13M, mean age 45 yrs w/ PsA ~6.2 yrs. 54% had 1st-degree relatives with PsA. 66% had DIP arthritis, 39% polyarticular, 36% oligoarticular, 25% were axial. Nail findings seen in 89%, enthesitis 59%, dactylitis 62% https://t.co/FPAqosYr9C https://t.co/xr692rSZZ1
Dr. John Cush RheumNow
3 years 5 months ago
Retrospective insurance claims study of PMR & GCA pts. No cases PJP (pneumocystis) found in 547 Pt-Yrs F/U in 1168 GCA pts and 1 case found during 7,446 Pt-Yrs F/U in 15,575 PMR pts (incident 0.07 cases per 1,000 Pt-YRs). NO NEED FOR PJP prophylaxis! https://t.co/UFlKtm88Dj https://t.co/tFYusx0O4t
An international task force of 13 European experts have developed evidence-based points to consider regarding the cost-effective use of biological and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) in the treatment of inflammatory rheumatic diseases (including rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis).
Dr. John Cush RheumNow
3 years 5 months ago
Long-Term Survival of Idiopathic Inflammatory Myopathies
A single center cohort study analyzed the outcome and survival of IIM patients and showed good 5 and 10 year survival but showed significant declined 15-25 years post-diagnosis.
https://t.co/EmxRcDCIVn https://t.co/ngtMgrO9Jc
